Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline

The Journal of Clinical Endocrinology and Metabolism
James L RosenzweigBruno L Vergès

Abstract

To develop clinical practice guidelines for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) and type 2 diabetes mellitus (T2DM) in individuals at metabolic risk for developing these conditions. Health care providers should incorporate regular screening and identification of individuals at metabolic risk (at higher risk for ASCVD and T2DM) with measurement of blood pressure, waist circumference, fasting lipid profile, and blood glucose. Individuals identified at metabolic risk should undergo 10-year global risk assessment for ASCVD or coronary heart disease to determine targets of therapy for reduction of apolipoprotein B-containing lipoproteins. Hypertension should be treated to targets outlined in this guideline. Individuals with prediabetes should be tested at least annually for progression to diabetes and referred to intensive diet and physical activity behavioral counseling programs. For the primary prevention of ASCVD and T2DM, the Writing Committee recommends lifestyle management be the first priority. Behavioral programs should include a heart-healthy dietary pattern and sodium restriction, as well as an active lifestyle with daily walking, limited sedentary time, and a structured program of phys...Continue Reading

References

Mar 1, 1988·Metabolism: Clinical and Experimental·E Ferrannini
Jul 15, 1995·BMJ : British Medical Journal·M E LeanC E Morrison
May 28, 1997·JAMA : the Journal of the American Medical Association·P K WheltonM J Klag
Apr 4, 1998·The American Journal of Cardiology·S M Grundy
May 29, 1998·Circulation·P W WilsonW B Kannel
Oct 29, 1998·Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society·R E De MeersmanJ A Downey
May 26, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·B Balkau, M A Charles
May 3, 2001·The New England Journal of Medicine·J TuomilehtoUNKNOWN Finnish Diabetes Prevention Study Group
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Apr 3, 2002·Annals of Internal Medicine·Seamus P WheltonJiang He
May 4, 2002·American Journal of Preventive Medicine·Evelyn P WhitlockJanet Allan
Jun 28, 2002·Lancet·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trail Research Group
Jul 10, 2002·Stroke; a Journal of Cerebral Circulation·Viti KothariRudy R Holman
Jul 18, 2002·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·T Pischon, A M Sharma
Sep 5, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·E Ferrannini, B Balkau
Nov 7, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·UNKNOWN Examination Committee of Criteria for 'Obesity Disease' in Japan, UNKNOWN Japan Society for the Study of Obesity
Nov 28, 2002·Diabetes Care·UNKNOWN Diabetes Prevention Program (DPP) Research Group
Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Oct 28, 2003·Diabetes Care·Saul GenuthUNKNOWN Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Oct 31, 2003·Journal of the American College of Surgeons·Eric R Frykberg
Apr 9, 2004·The New England Journal of Medicine·John DaneshVilmundur Gudnason
May 27, 2004·Diabetes Care·James B MeigsPeter W F Wilson
Aug 20, 2004·Journal of Clinical Pharmacology·Arthur J BergmanJohn F Paolini
Aug 28, 2004·Diabetes Research and Clinical Practice·A RamachandranV Vijay
Oct 16, 2004·Obesity Research·Rena R WingUNKNOWN Diabetes Prevention Program Research Group

❮ Previous
Next ❯

Citations

Nov 2, 2019·Neurology·Laurel A Beckett, Lars F Berglund
Sep 17, 2020·Diabetes Care·Mayer B Davidson
Sep 21, 2020·The Journal of Clinical Endocrinology and Metabolism·Connie B NewmanLisa R Tannock
Feb 8, 2020·Journal of the American College of Cardiology·Jeffrey I MechanickW Timothy Garvey
Mar 17, 2020·Atherosclerosis·Xiangdong WuKevin Jon Williams
May 1, 2021·Frontiers in Endocrinology·Kasiphak KaikaewJenny A Visser
Aug 18, 2021·Endocrinology and Metabolism Clinics of North America·Daisy DuanJustin B Echouffo-Tcheugui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.